1. Clinical Overview
Pancreatin is a standardized, porcine-derived pancreatic enzyme preparation containing a mixture of lipase, protease, and amylase. The 40000PFU strength refers to its lipase activity of 40,000 Ph. Eur. Units (equivalent to 40,000 USP Units). It is an essential enzyme replacement therapy used to correct exocrine pancreatic insufficiency (EPI) by aiding the digestion of fats, proteins, and carbohydrates in the duodenum. It is formulated as gastro-resistant (enteric-coated) microspheres or microtablets to protect the enzymes from gastric acid inactivation.
| Onset | Duration | Bioavailability |
|---|---|---|
| Onset of digestive action begins within 30-45 minutes of ingestion, coinciding with gastric emptying and release of enzymes in the duodenum. | Duration is limited to the digestive phase of the meal, typically 1-2 hours, as enzymes are degraded and excreted. | Not applicable in the conventional sense. Enzymes act locally within the gastrointestinal lumen and are not systemically absorbed. The therapeutic efficacy is measured by clinical parameters like fecal fat excretion and nutritional status. |
2. Mechanism of Action
Pancreatin compensates for deficient exocrine pancreatic secretion. The enteric-coated formulation protects the enzymes from denaturation by gastric acid. The coating dissolves at a pH > 5.5 (typically in the duodenum), releasing active enzymes. Lipase hydrolyzes triglycerides into monoglycerides and free fatty acids. Proteases (trypsin, chymotrypsin) break down proteins into peptides and amino acids. Amylase hydrolyzes starch into dextrins and sugars.
3. Indications & Uses
- Exocrine Pancreatic Insufficiency (EPI) due to Chronic Pancreatitis
- Exocrine Pancreatic Insufficiency due to Cystic Fibrosis
- Exocrine Pancreatic Insufficiency following Pancreatectomy
4. Dosage & Administration
Adult Dosage: Highly individualized. Initial dose often ranges from 25,000 to 40,000 Ph. Eur. Units of lipase per main meal, and half that amount per snack. The dose is titrated based on symptoms (stool frequency, consistency) and nutritional parameters. Typical maintenance dose for severe EPI: 40,000-80,000 U lipase/meal.
Administration: Take with each meal or snack. Swallow capsules whole with a glass of water; DO NOT crush or chew. For patients unable to swallow capsules (e.g., children), the contents can be mixed with a small amount of soft, acidic food (e.g., apple sauce, yogurt, fruit puree) at room temperature and swallowed immediately without chewing. Do not mix with alkaline foods or hot foods. Take while sitting upright.
5. Side Effects
Common side effects may include:
- Abdominal discomfort
- Flatulence
- Nausea
- Diarrhea or constipation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Antacids (containing Calcium Carbonate or Magnesium Hydroxide) | May raise gastric pH prematurely, dissolving the enteric coating in the stomach and inactivating enzymes. | Moderate |
| H2-Receptor Antagonists (e.g., Famotidine) / Proton Pump Inhibitors (e.g., Omeprazole) | May be co-prescribed to ensure a higher duodenal pH for optimal enzyme release, especially in patients with low duodenal pH. This is often a beneficial interaction in EPI management. | Beneficial/Moderate |
| Acarbose / Miglitol | Theoretical interaction as both affect carbohydrate digestion. Clinical significance is unclear. | Mild |
| Orlistat | Both inhibit fat absorption via different mechanisms. Concomitant use is not recommended. | Major |
7. Patient Counselling
- DO take the capsule with every meal or substantial snack.
- DO swallow the capsule whole with plenty of water.
- DO inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- DO NOT crush, chew, or hold the capsule/microspheres in your mouth.
- DO NOT take the dose on an empty stomach.
- DO NOT mix the capsule contents with hot food or alkaline foods (like milk).
8. Toxicology & Storage
Overdose: Very high doses may cause nausea, vomiting, diarrhea, abdominal cramps, and hyperuricemia. In children with cystic fibrosis, chronic overdose is associated with fibrosing colonopathy.
Storage: Store below 25°C in a cool, dry place. Protect from moisture. Keep in the original container. Do not refrigerate. Keep out of reach of children.